Report cover image

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Feb 10, 2025
Length 189 Pages
SKU # APRC19876177

Description

Summary

Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.

The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.

According to APO Research, The global Amyotrophic Lateral Sclerosis (ALS) Treatment market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Amyotrophic Lateral Sclerosis (ALS) Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Amyotrophic Lateral Sclerosis (ALS) Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Amyotrophic Lateral Sclerosis (ALS) Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Amyotrophic Lateral Sclerosis (ALS) Treatment is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Amyotrophic Lateral Sclerosis (ALS) Treatment include Mitsubishi Tanabe Pharma, Sanofi, Mylan Pharma, Apotex, Glemark Generics, Covis Pharma, Sun Pharma and Lunan Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes


This report presents an overview of global market for Amyotrophic Lateral Sclerosis (ALS) Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Amyotrophic Lateral Sclerosis (ALS) Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Amyotrophic Lateral Sclerosis (ALS) Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Amyotrophic Lateral Sclerosis (ALS) Treatment revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Amyotrophic Lateral Sclerosis (ALS) Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Amyotrophic Lateral Sclerosis (ALS) Treatment revenue, projected growth trends, production technology, application and end-user industry.


Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Company

Mitsubishi Tanabe Pharma
Sanofi
Mylan Pharma
Apotex
Glemark Generics
Covis Pharma
Sun Pharma
Lunan Pharma

Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Type

Riluzole
Edaravone (Radicava)
Other

Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Application

Hospital
Drugs Store
Other

Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Amyotrophic Lateral Sclerosis (ALS) Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Amyotrophic Lateral Sclerosis (ALS) Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Amyotrophic Lateral Sclerosis (ALS) Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Amyotrophic Lateral Sclerosis (ALS) Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Amyotrophic Lateral Sclerosis (ALS) Treatment industry.
Chapter 3: Detailed analysis of Amyotrophic Lateral Sclerosis (ALS) Treatment companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Amyotrophic Lateral Sclerosis (ALS) Treatmentrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

189 Pages
1 Market Overview
1.1 Product Definition
1.2 Market Analysis by Type
1.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Riluzole
1.2.3 Edaravone (Radicava)
1.2.4 Other
1.3 Market Analysis by Application
1.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Drugs Store
1.3.4 Other
1.4 Global Market Growth Prospects
1.5 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Growth Trends by Region
1.5.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region: 2020 VS 2024 VS 2031
1.5.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2020-2025)
1.5.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2026-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
1.8 Years Considered
2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Dynamics
2.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Trends
2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Drivers
2.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Opportunities and Challenges
2.4 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Restraints
3 Competitive Landscape by Company
3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Company (2020-2025)
3.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Players Revenue Ranking, 2023 VS 2024 VS 2025
3.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Key Company Head office and Area Served
3.4 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Company, Product Type & Application
3.5 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Company Establishment Date
3.6 Market Competitive Analysis
3.6.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market CR5 and HHI
3.6.2 Global Top 5 and 10 Amyotrophic Lateral Sclerosis (ALS) Treatment Players Market Share by Revenue in 2024
3.6.3 2024 Amyotrophic Lateral Sclerosis (ALS) Treatment Tier 1, Tier 2, and Tier 3
4 Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Type
4.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2020 VS 2024 VS 2031)
4.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2020-2031)
4.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Share by Type (2020-2031)
5 Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Application
5.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2020 VS 2024 VS 2031)
5.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2020-2031)
5.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Share by Application (2020-2031)
6 Company Profiles
6.1 Mitsubishi Tanabe Pharma
6.1.1 Mitsubishi Tanabe Pharma Comapny Information
6.1.2 Mitsubishi Tanabe Pharma Business Overview
6.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2020-2025)
6.1.4 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
6.1.5 Mitsubishi Tanabe Pharma Recent Developments
6.2 Sanofi
6.2.1 Sanofi Comapny Information
6.2.2 Sanofi Business Overview
6.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2020-2025)
6.2.4 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
6.2.5 Sanofi Recent Developments
6.3 Mylan Pharma
6.3.1 Mylan Pharma Comapny Information
6.3.2 Mylan Pharma Business Overview
6.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2020-2025)
6.3.4 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
6.3.5 Mylan Pharma Recent Developments
6.4 Apotex
6.4.1 Apotex Comapny Information
6.4.2 Apotex Business Overview
6.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2020-2025)
6.4.4 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
6.4.5 Apotex Recent Developments
6.5 Glemark Generics
6.5.1 Glemark Generics Comapny Information
6.5.2 Glemark Generics Business Overview
6.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2020-2025)
6.5.4 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
6.5.5 Glemark Generics Recent Developments
6.6 Covis Pharma
6.6.1 Covis Pharma Comapny Information
6.6.2 Covis Pharma Business Overview
6.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2020-2025)
6.6.4 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
6.6.5 Covis Pharma Recent Developments
6.7 Sun Pharma
6.7.1 Sun Pharma Comapny Information
6.7.2 Sun Pharma Business Overview
6.7.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2020-2025)
6.7.4 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
6.7.5 Sun Pharma Recent Developments
6.8 Lunan Pharma
6.8.1 Lunan Pharma Comapny Information
6.8.2 Lunan Pharma Business Overview
6.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Gross Margin (US$ Million) & (2020-2025)
6.8.4 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
6.8.5 Lunan Pharma Recent Developments
7 North America
7.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2020-2031)
7.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
7.2.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2020-2025)
7.2.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2026-2031)
7.2.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type (2020-2031)
7.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application
7.3.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2020-2025)
7.3.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2026-2031)
7.3.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application (2020-2031)
7.4 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country
7.4.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2020 VS 2024 VS 2031)
7.4.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2020-2025)
7.4.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2026-2031)
7.4.4 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2020-2031)
7.4.5 United States
7.4.6 Canada
7.4.7 Mexico
8 Europe
8.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2020-2031)
8.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
8.2.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2020-2025)
8.2.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2026-2031)
8.2.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type (2020-2031)
8.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application
8.3.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2020-2025)
8.3.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2026-2031)
8.3.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application (2020-2031)
8.4 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country
8.4.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2020 VS 2024 VS 2031)
8.4.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2020-2025)
8.4.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2026-2031)
8.4.4 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2020-2031)
8.4.5 Germany
8.4.6 France
8.4.7 U.K.
8.4.8 Italy
8.4.9 Russia
8.4.10 Nordic Countries
9 China
9.1 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2020-2031)
9.2 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
9.2.1 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2020-2025)
9.2.2 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2026-2031)
9.2.3 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type (2020-2031)
9.3 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application
9.3.1 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2020-2025)
9.3.2 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2026-2031)
9.3.3 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application (2020-2031)
10 Asia (Excluding China)
10.1 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2020-2031)
10.2 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
10.2.1 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2020-2025)
10.2.2 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2026-2031)
10.2.3 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type (2020-2031)
10.3 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application
10.3.1 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2020-2025)
10.3.2 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2026-2031)
10.3.3 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application (2020-2031)
10.4 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country
10.4.1 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2020 VS 2024 VS 2031)
10.4.2 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2020-2025)
10.4.3 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2026-2031)
10.4.4 Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2020-2031)
10.4.5 Japan
10.4.6 South Korea
10.4.7 Taiwan
10.4.8 Southeast Asia
10.4.9 India
10.4.10 Australia
11 South America, Middle East & Africa
11.1 South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2020-2031)
11.2 South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
11.2.1 South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2020-2025)
11.2.2 South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2026-2031)
11.2.3 South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type (2020-2031)
11.3 South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application
11.3.1 South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2020-2025)
11.3.2 South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2026-2031)
11.3.3 South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application (2020-2031)
11.4 South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country
11.4.1 South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2020 VS 2024 VS 2031)
11.4.2 South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2020-2025)
11.4.3 South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2026-2031)
11.4.4 South America, Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2020-2031)
11.4.5 Brazil
11.4.6 South Africa
11.4.7 Saudi Arabia
11.4.8 Turkey
11.4.9 Argentina
11.4.9 UAE
11.4.9 Egypt
11.4.9 Chile
12 Concluding Insights
13 Appendix
13.1 Reasons for Doing This Study
13.2 Research Methodology
13.3 Research Process
13.4 Authors List of This Report
13.5 Data Source
13.5.1 Secondary Sources
13.5.2 Primary Sources
13.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.